The GLP-1 Gold Rush: Will Trump Rewrite the Rules for Eli Lilly and Novo Nordisk?

The Bidding Blitz: Why Novo Nordisk's Loss to Pfizer Isn't Just About Money

The Numbers Are In: Immunome's Latest Quarter Falls Short, Raising Eyebrows on Wall Street

Against the Odds: Curis Delivers an Unexpected Earnings Victory

Immunome's Latest Financial Dive: More Than Just Numbers on a Page

Intellia Shakes Up Expectations: A Deep Dive into Their Q1 Surprise

The Pulse of Progress: Why Healthcare Stocks Are Sparking Investor Interest Right Now

The Race for a Breakthrough: Pfizer's Bold Bet on Battling Obesity, Outmaneuvering Novo Nordisk

The Great Weight-Loss Gambit: Pfizer Jumps into the Billion-Dollar Battle for Obesity Treatment Supremacy

The CRISPR Revolution: A One-Time Fix for a Lifelong Problem? Unpacking the Future of Cholesterol Treatment

A Deeper Dive: Unraveling the Intricate Pulse of Medical Sector Investments

The Biotech Rollercoaster: Moderna Defies Gravity with a Q3 Power Play

The FDA's Tightening Grip: A Crucible for Biotech's Biggest Bets

The Shifting Sands of Scalp Science: Biotech's Bold Bet on Regrowing What We've Lost

Unlocking the Mind's Mysteries: How AI is Rewriting the Future of Brain Health

The Pharma Gambit: Why Pfizer Might Just Snatch Metsara from Novo's Grasp

The Watchdogs Are Barking: Why Metsera's Big Deal Just Hit a Snag

Rigel's Stunning Leap: A New Chapter Unfolds for the Biotech Challenger

Aurinia Finds Its Rhythm: Strong Q3 Results Spark Investor Enthusiasm

The Cancer Code: How One Biotech's 'Probody' Just Sparked Hope (and a Stock Surge)

The High Stakes Game: Sarepta, Duchenne, and the Edge of Hope

Caught in the Crossfire: Pfizer Accuses Novo Nordisk of Sabotaging a Critical Biotech Merger

The Rocket Ride: How Intensity Therapeutics Ignited Wall Street (and Hope) with its Cancer Breakthrough

The Billion-Dollar Standoff: Pfizer Unleashes on Novo Nordisk in Metsera Bid Battle

The CRISPR Crusade: Intellia's Ambitious Leap into the Heart of AML

The Great Biotech Reckoning: Moderna's Wild Ride from Pandemic Hero to Post-COVID Crossroads

A Sudden Chill for Intellia: FDA Hits Pause on Groundbreaking Gene Therapy Trial

Biotech's Pulse Check: AI Rises, a Cancer Test Stumbles, and a Rare Disease Shines

A Glimmer of Hope: Anavex's Alzheimer's Drug Shows Enduring Promise

The $8.9 Billion Bet: Thermo Fisher's Bold Play to Redefine Clinical Trials

The Great Biotech Reckoning: Can Washington and Beijing Find Common Ground (Or Just More Friction)?

The Unseen Surge: What Sent Profusa Stock Skyrocketing After Hours?

The Nicotine Revolution? How One Company Just Cracked the Code (and Sent Its Stock Soaring)

The Grand Alliance: Eli Lilly, NVIDIA, and the Supercomputer Set to Reshape Medicine

The Shifting Pulse: Could Dr. Casey Means Reshape America's Health as Surgeon General?

Regeneron's Remarkable Q3: A Dupixent-Driven Triumph That Reaffirms Biotech's Pulse

The Biotech Beat: Unpacking a Week of Breakthroughs, Billions, and Big Bets

From Desert Sands to Life Science Dreams: WuXi AppTec's Bold Move into Saudi Arabia

The Unsung Heroes of Immunity: How One Scientist Is Unlocking the Macrophage's Secrets Against Cancer